Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 2, 2016, Pages 428-437

  So, Wonhee ^a   Crandon, Jared L ^a   Hamada, Yukihiro ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG EXPOSURE; EPITHELIAL LINING FLUID; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; ADULT; AGED; BODY FLUID; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADULT; AGED; AMIKACIN; ANTI-BACTERIAL AGENTS; BODY FLUIDS; FEMALE; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; THIENAMYCINS; YOUNG ADULT;

EID: 84959906057     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv370     Document Type: Article

References (47)

1. Barbier F, Andremont A, WolffM et al. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013; 19: 216-28.
2. Abu-Salah T, Dhand R. Inhaled antibiotic therapy for ventilatorassociated tracheobronchitis and ventilator associated pneumonia: an update. Adv Ther 2011; 28: 728-47.
3. Forel JM, Voillet F, Pulina D et al. Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lungprotective strategy. Crit Care 2012; 16: R65.
4. Chung Dr, Song JH, Kim SH et al. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia. Am J Respir Crit Care Med 2011; 184: 1409-17.
5. Ferrer M, Liapikou A, ValenciaM. et al. Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital acquired pneumonia in the intensive care unit. Clin Infect Dis 2010; 50: 945-52.
6. Lee MS, Walker W, Chen LF et al. The epidemiology of ventilatorassociated pneumonia in a network of community hospitals: a prospective multicenter study. Infect Control Hosp Epidemiol 2013; 34: 657-62.
7. Boselli E, Brilh D, Djabarouti S et al. Reliability of minibronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive CareMed 2007; 33: 1519-23.
8. Niederman MS, Chastre J, Corkery K et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012; 38: 263-71.
9. Dhand R, Sohal H. Pulmonary Drug Delivery Systemfor inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008; 5: 9-18.
10. Luyt CE, Clavel M, Guntupalli K et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 2009; 13: R200.
11. McGann P, Courvalin P, Snesrud E et al. Amplification of aminoglycoside resistance gene aphA1 in Acinetobacter baumannii results in tobramycin therapy failure. MBio 2014; 5: e00915.
12. McGann P, Snesrud E, Ong AC et al. War wound treatment complications due to transfer of an IncN plasmid harboring blaOXA-181 from Morganella morganii to CTX-M-27-producing ST131 Escherichia coli. Antimicrob Agents Chemother 2015; 59: 3556-62.
13. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
14. Stass H, Willmann S, Wendl T. Risk assessment for amikacin inhale in ICU patients using whole-body physiologically based PK-models. In: Abstracts of the Forty-third Critical Care Congress, San Francisco, CA, 2014. Abstract 926. Society of Critical Care Medicine, Mount Prospect, IL, USA.
15. Luyt CE, Eldon MA, Stass H et al. Pharmacokinetics and tolerability of amikacin administered as BAY41-6551 aerosol in mechanically ventilated patients with Gram-negative pneumonia and acute renal failure. J Aerosol Med Pulm Drug Deliv 2011; 24: 183-90.
16. Lodise TP, Sorgel F, Melnick D et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2011; 55: 1606-10.
17. Drusano GL, Sorgel F, Quinn J et al. Impact of pharmacodynamics dosing of meropenem on emergence of resistance during treatment of ventilator-associated pneumonia: a prospective clinical trial. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract K-127. American Society for Microbiology, Washington, DC, USA.
18. Wiskirchen DE, Koomanachai P, Nicasio AM et al. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline along and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 2005; 55: 1420-7.
19. Elkhaili H, Niedergang S, Pompei D et al. High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl 1996; 686: 19-26.
20. Bulik CC, Christensen H, Li P et al. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2010; 54: 804-10.
21. Sader HS, Rhomberg PR, Farrell DJ et al. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother 2015; 59: 3263-70.
22. Almaghrabi R, Clancy CJ, Doi Y et al. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effect on plazomicin and other agents. Antimicrob Agents Chemother 2014; 58: 4443-51.
23. Zelenitsky SA, Rubinstein E, Ariano R et al. Integrating pharmacokinetics, pharmacodynamics and MIC distribution to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD). J Antimicrob Chemother 2013; 68 Suppl 1: i67-72.
24. Vaziri F, Peerayeh SN, Nejad QB et al. The prevalence of aminoglycosidemodifying enzyme genes (aac(6')-I, aac(6')-II, ant(2'')-I, aph(3')-VI) in Pseudomonas aeruginosa. Clinics (Sao Paulo) 2011; 66: 1519-22.
25. Wachino JI, Arakawa Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. Drug Resist Updat 2012; 15: 133-48.
26. Tijet N, Andres P, Chung C et al. rmtD2, a new allele of a 16S rRNA methylase gene, has been present in Enterobacteriaceae isolates from Argentina for more than a decade. Antimicrob Agents Chemother 2011; 55: 904-9.
27. Park YJ, Lee SG, Y JK et al. Co-production of 16S rRNA methylases and extended-spectrum β-lactamases in AmpC-producing Enterobacter cloacae, Citrobacter freundii and Serratia marcescens in Korea. J Antimicrob Chemother 2006; 58: 907-8.
28. Kang HY, Kim KY, Kim J et al. Distribution of conjugative-plasmidmediated 16S rRNA methylase genes among amikacin-resistant Enterobacteriaceae isolates collected in 1995 to 1998 and 2001 to 2006 at a university hospital in South Korea and identification of conjugative plasmids mediating dissemination of 16S rRNA methylase. J Clin Microbiol 2008; 46: 700-6.
29. Yu FY, Yao D, Pan JY et al. High prevalence of plasmid-mediated 16S rRNA methylase gene rmtB among Escherichia coli clinical isolates from a Chinese teaching hospital. BMC Infect Dis 2010; 10: 184.
30. Bell JM, Andersson P, Jones R et al. 16S rRNA methylase containing Enterobacteriaceae in the SENTRY Asia-Pacific region frequently harbor plasmid-mediated quinolone resistance and CTXM types. In: Abstracts of the Twentieth European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 2010. Abstract O559. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
31. Shaw KJ, Rather PN, Hare RS et al. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycosidemodifying enzymes. Microb Rev 1993; 57: 138-63.
32. Aghazadeh M, Rezaee MA, Nahaei MR et al. Dissemination of aminoglycoside-modifying enzymes and 16S rRNA methylases among Acinetobacter baumannii and Pseudomonas aeruginosa isolates. Microb Drug Resist 2013; 19: 282-8.
33. Haldorsen BC, Simonsen GS, Sundsfjord A et al. Increased prevalence of aminoglycoside resistance in clinical isolates of Escherichia coli and Klebsiella spp. in Norway is associated with the acquisition of AAC(3)-II and AAC(6')-Ib. Diag Microb Infect Dis 2014; 78: 66-9.
34. Lambert T. Aminoglycosides and Gram-negative bacteria. In: Couvalin P, Leclercq R, Rice LB, eds. Antibiogram. Portland: ESKA Publishing, 2010; 225-42.
35. Gurung M, Moon DC, Tamang MD et al. Emergence of 16S rRNA methylase gene armA and cocarriage of blaIMP-1 in Pseudomonas aeruginosa isolates from South Korea. Diagn Microbiol Infect Dis 2010; 68: 468-70.
36. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9.
37. Pajot O, Burdet C, Couffignal C et al. Impact of impanel and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia. J Antimicrob Chemother 2015; 70: 1487-94.
38. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003; 36 Suppl 1: S42-50.
39. Ong CT, Tessier PR, Li C et al. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis 2007; 57: 153-61.
40. DeRyke CA, Banevicius MA, Fan HW. et al. Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactam aseproducing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother 2007; 51: 1481-6.
41. Le J, McKee B, Srisupha-Olarn W. et al. In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae. J Clin Med Res 2011; 3: 106-10.
42. Clock SA, Tabibi S, Alba L et al. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae. Diag Microbiol Infect Dis 2013; 76: 343-6.
43. Palmer LB, Smaldone GC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med 2014; 189: 1225-33.
44. Lu Q, Yang J, Liu Z et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 184: 106-15.
45. Kumari H, Balasubramanian D, Zincke D et al. Role of Pseudomonas aeruginosa AmpR on β-lactam and non-β-lactam transient crossresistance upon pre-exposure to subinhibitory concentrations of antibiotics. J Med Microbiol 2014; 63: 544-55.
46. Luyt CE, Aubry A, Lu Q et al. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother 2014; 58: 1372-80.
47. Chen YG, Zhang Y, Yu YS et al. In vivo development of carbapenem resistance in clinical isolates of Enterobacter aerogenes producing multiple β-lactamases. Int J Antimicrob Agents 2008; 32: 302-7.